Document is current
Any future updates will be listed below
-
Authors
Hardman, Clare S. https://orcid.org/0000-0002-1127-6446
Chen, Yi-Ling https://orcid.org/0000-0003-3758-0638
Wegrecki, Marcin https://orcid.org/0000-0002-3275-9850
Ng, Soo Weei https://orcid.org/0000-0002-9867-6353
Murren, Robert
Mangat, Davinderpreet
Silva, John-Paul
Munro, Rebecca
Chan, Win Yan https://orcid.org/0000-0001-6964-5091
O’Dowd, Victoria
Doyle, Carl
Mori, Prashant
Popplewell, Andy
Rossjohn, Jamie https://orcid.org/0000-0002-2020-7522
Lightwood, Daniel https://orcid.org/0000-0003-1433-7459
Ogg, Graham S. https://orcid.org/0000-0002-3097-045X
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MC_EX_MR/R022550/1)
RCUK | Medical Research Council (MC_UU_00008)
UCB | UCB UK
- License Information
-
More Information
Article History
Received: 15 November 2021
Accepted: 17 November 2022
First Online: 7 December 2022
Competing interests
: C.S.H., Y.-L.C. and G.S.O. are on filed patents pertaining to the antibodies. R. Murren, D.M., J.P.S., R. Munro, W.Y.C., V.O.D., C.D., P.M., A.P. and D.L. are employees of UCB Pharma, which has initial licensing rights to the antibodies. The authors have no additional competing interests to declare.
